19 reports

  • 3.1 Overview

TABLE ##: GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, FORECAST REVENUE BY COMPANY, 2015-2022 Shionogi ## ## ## ## ## ## ## ## -##. ## -##. ## -##. ## Ipsen - ## ## ## ## ## ## ## - - ##. ## GW - - ## ## ## ## ## ## ##. ## ##. ## ##. ## Almirall - ## ##

  • Gastrointestinal Drug
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

You can easily book an appointment with one online.

  • Gastrointestinal Drug
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

The company also supported the Ministry of Health in the organisation of an event dedicated to World Tuberculosis Day.

  • Acne Treatment
  • Gastrointestinal Drug
  • OTC
  • Kazakhstan
  • Demand

Drivers and their Impact Impact on key customer category disease Increase in patient population Regulatory and distribution channel Non-complex etiology Growing geriatric population framework Low Low ## ## ## ## ## High High ## ## ## ## ## ## ## ## ## ## Low High ## ## ## ## ##

  • Gastrointestinal Drug
  • World
  • GlaxoSmithKline plc
  • Perrigo Company
  • Pfizer Inc.
  • FEATURED NEWS & PRESS RELEASES
  • FEATURED NEWS & PRESS RELEASES

The molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/ CTA Filed and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • AstraZeneca PLC

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.

IBS is one of the most common gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company Operations
  • RedHill Biopharma Ltd.

ASP-## is a selective COX ##(cyclooxygenases-##) inhibitor.

  • Gastrointestinal Drug
  • United States
  • Litigation And Patent
  • Product Initiative
  • AstraZeneca PLC

Its lead product, AKT##, is under development for treatment of watery diarrhea and opportunistic gastro-intestinal infections (Clostridium difficile) and as an adjunct therapy in tuberculosis.

  • Gastrointestinal Drug
  • Infectious Disease
  • China
  • World
  • Product Initiative
  • AKT-10081 - DRUG PROFILE
  • DIARRHEA - PIPELINE BY ALBIREO PHARMA INC, H1 2018

Diarrhea - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H1 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape. Diarrhea is a contagious gastrointestinal infection...

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Company
  • Product Initiative
  • DIARRHEA - PIPELINE BY AKTHELIA PHARMACEUTICALS LTD, H2 2017
  • DIARRHEA - PIPELINE BY AEGIS THERAPEUTICS LLC, H2 2017

## ## ## ## ## ## ## ## ## ## ## ## ## ## ## P II ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## PC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Dis ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Anti-Infective
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • Synthetic Biologics
  • Clinical Trial profile. 259 Trial Title

Nausea Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Nausea Global Clinical Trials Review, H1, 2018" provides an overview of Nausea clinical trials scenario.This report provides top line data relating to the clinical trials on Nausea. Report includes...

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Merck & Co., Inc.

The company' s lead product, AKT##, is under development for treatment of watery diarrhea and opportunistic gastro-intestinal infections (Clostridium difficile) and as an adjunct therapy in tuberculosis.

  • Gastrointestinal Drug
  • World
  • Company Operations
  • Company Sales
  • Product Initiative
  • REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) - PIPELINE BY YOOYOUNG PHARM CO LTD, H1 2018

Patients were randomly assigned to one of two arms - one arm received Insegia alone, the other arm received placebo.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • United States
  • Product Initiative
  • RaQualia Pharma Inc.

The institute' s research areas include infectious diseases such as tuberculosis and influenza, HIV/ AIDS, biodefense; and immune-mediated diseases including asthma and allergy.

  • Biopharmaceutical
  • Gastrointestinal Drug
  • United States
  • Company Financials
  • RedHill Biopharma Ltd.
  • REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) - PIPELINE BY YOOYOUNG PHARM CO LTD, H2 2017
  • REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) - PIPELINE BY YUYU PHARMA INC, H2 2017

Patients were randomly assigned to one of two arms - one arm received Insegia alone, the other arm received placebo.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Healthcare
  • World
  • Product Initiative
  • Official Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • World
  • Product Initiative